Treatment with growth hormone for adults with growth hormone deficiency syndrome: benefits and risks

UDC.coleccionInvestigaciónes_ES
UDC.departamentoFisioterapia, Medicina e Ciencias Biomédicases_ES
UDC.grupoInvGrupo Fisiopatoloxía Endócrina, Nutricional e Médica (FENM)es_ES
UDC.grupoInvEnfermidades Endocrinas, Nutricionais e Metabólicas (INIBIC)es_ES
UDC.institutoCentroINIBIC - Instituto de Investigacións Biomédicas de A Coruñaes_ES
UDC.issue3es_ES
UDC.journalTitleInternational Journal of Molecular Scienceses_ES
UDC.startPage893es_ES
UDC.volume19es_ES
dc.contributor.authorDíez, Juan José
dc.contributor.authorSangiao-Alvarellos, Susana
dc.contributor.authorCordido, Fernando
dc.date.accessioned2018-04-06T08:43:01Z
dc.date.available2018-04-06T08:43:01Z
dc.date.issued2018-03-17
dc.description.abstract[Abstract] Pharmacological treatment of growth hormone deficiency (GHD) in adults began in clinical practice more than 20 years ago. Since then, a great volume of experience has been accumulated on its effects on the symptoms and biochemical alterations that characterize this hormonal deficiency. The effects on body composition, muscle mass and strength, exercise capacity, glucose and lipid profile, bone metabolism, and quality of life have been fully demonstrated. The advance of knowledge has also taken place in the biological and molecular aspects of the action of this hormone in patients who have completed longitudinal growth. In recent years, several epidemiological studies have reported interesting information about the long-term effects of GH replacement therapy in regard to the possible induction of neoplasms and the potential development of diabetes. In addition, GH hormone receptor polymorphism could potentially influence GH therapy. Long-acting GH are under development to create a more convenient GH dosing profile, while retaining the excellent safety, efficacy, and tolerability of daily GH. In this article we compile the most recent data of GH replacement therapy in adults, as well as the molecular aspects that may condition a different sensitivity to this treatment.es_ES
dc.description.sponsorshipSupported in part by: FIS del Instituto de Salud Carlos III PI13/00322 and PI16/00884 (FEDER from E.U.) and Xunta de Galicia 10CSA916014PR, Spain.es_ES
dc.description.sponsorshipinfo:eu-repo/grantAgreement/MINECO/Programa Estatal de I+D+I Orientada a los Retos de la Sociedad/PI13%2F00322/ES/EVOLUCION DE LAS HORMONAS GASTROINTESTINALES TRAS LA DISMINUCION DE LA ADIPOSIDAD Y LA MODIFICACIÓN DE LOS NIVELES DE GH. EL EJE CEREBRO-INTESTINOes_ES
dc.description.sponsorshipXunta de Galicia; 10CSA916014PRes_ES
dc.description.sponsorshipinfo:eu-repo/grantAgreement/MINECO/Programa Estatal de I+D+I Orientada a los Retos de la Sociedad/PI16%2F00884/ES/RELACION ENTRE MARCADORES HORMONALES DE CONTROL DE LA INGESTA Y GASTO METABÓLICO. EFECTO DEL BALANCE ENERGÉTICO NEGATIVO Y LA MODIFICACIÓN DE GH
dc.identifier.citationDíez JJ, Sangiao-Alvarellos S, Cordido F. Treatment with growth hormone for adults with growth hormone deficiency syndrome: benefits and risks. Int J Mol Sci. 2018 Mar 17;19(3):893.es_ES
dc.identifier.issn1422-0067
dc.identifier.urihttp://hdl.handle.net/2183/20387
dc.language.isoenges_ES
dc.publisherMDPIes_ES
dc.relation.urihttp://dx.doi.org/10.3390/ijms19030893es_ES
dc.rightsCreative Commons Attribution 4.0 International License (CC-BY 4.0)es_ES
dc.rights.accessRightsopen accesses_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectGrowth hormonees_ES
dc.subjectGrowth hormone deficiencyes_ES
dc.subjectHypopituitarismes_ES
dc.subjectTreatmentes_ES
dc.titleTreatment with growth hormone for adults with growth hormone deficiency syndrome: benefits and riskses_ES
dc.typejournal articlees_ES
dspace.entity.typePublication
relation.isAuthorOfPublicationad7947dc-e24a-4d34-a5d4-890279abcf48
relation.isAuthorOfPublicationdf28f954-c072-4ef1-b629-d6af3945bd92
relation.isAuthorOfPublication.latestForDiscoveryad7947dc-e24a-4d34-a5d4-890279abcf48

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Diez_Trtment.pdf
Size:
291.54 KB
Format:
Adobe Portable Document Format
Description: